Fulvestrant– An Anti-cancer Drug ,CAS No.: 129453-61-8

Introduction

Cancer has become a global threat, and every year, it claims millions of lives worldwide. One of the main challenges in cancer treatment is finding the right drugs that can effectively combat cancer cells without harming healthy body cells. Fulvestrant (CAS No.:129453-61-8) is an anti-cancer drug that has shown promising results in fighting breast cancer, making it one of the most sought after cancer treatments in the world. In this article, we shall delve deep into the main aspects of fulvestrant as a cancer drug and what makes it a reliable cancer therapy that merchants should consider.

Overview of Fulvestrant

Fulvestrant is a selective estrogen receptor antagonist (SERM) that is used in the treatment of hormone receptor-positive advanced breast cancer in postmenopausal women. It helps reduce the levels of estrogen hormones in the body, which are known to stimulate the growth of breast cancer cells. Fulvestrant works by binding to and down-regulating the estrogen receptor (ER) and inhibiting the ER signaling pathway that stimulates the growth of breast cancer cells. It is administered through injection and has been known to offer improved progression-free survival (PFS) in patients with advanced breast cancer, compared to other hormonal therapies.

Mechanism of Action

Fulvestrant has a distinct mechanism of action compared to other hormonal therapies such as tamoxifen, which is a selective ER modulator. Tamoxifen acts as a partial agonist or antagonist, depending on the target tissue, whereas fulvestrant acts as a complete ER antagonist. Fulvestrant works by binding competitively and irreversibly to the ER, inhibiting the ER signaling pathway and the growth of breast cancer cells. Once injected, fulvestrant binds to the ER and causes its degradation through a proteasomal pathway. This leads to the suppression of ER-dependent genes, which are responsible for the growth of cancer cells. Fulvestrant has a long half-life and is slowly released into the bloodstream, making it ideal for patients who require less frequent injections.

Clinical Studies

The efficacy of fulvestrant has been evaluated in several clinical trials, and the results have been promising. In one study conducted on postmenopausal women with advanced breast cancer, it was found that patients who received fulvestrant had significantly improved progression-free survival (PFS) compared to those who received anastrozole, another hormonal therapy. The study also showed that fulvestrant was better tolerated by patients and had a low toxicity profile. Another study conducted on patients with locally advanced or metastatic breast cancer also showed that fulvestrant improved PFS compared to anastrozole. It was also well-tolerated, with fewer side effects compared to tamoxifen.

Dosage and Administration

Fulvestrant is a prescription drug that is administered through injection, and the dosage may vary depending on the patient's medical history, age, weight, and response to treatment. The recommended dosage is 500mg, administered as two 5ml injections on the first day, followed by a 250mg injection on the 15th day, and thereafter, a 250mg injection every 28 days. It is essential to follow the dosage instructions provided by the physician to achieve maximum benefits and avoid any adverse effects.

Side Effects

Like any other drug, fulvestrant has its fair share of side effects, although they are generally mild and well-tolerated. The most common side effects include pain at the injection site, hot flashes, nausea, fatigue, headache, and musculoskeletal pain. More severe side effects such as allergic reactions, liver problems, and thrombosis are rare but may occur. Patients should notify their healthcare provider immediately if they experience any unusual side effects.

Conclusion

Fulvestrant is a reliable anti-cancer drug that has shown excellent results in the treatment of hormone receptor-positive advanced breast cancer. Its unique mechanism of action and low toxicity profile make it an ideal therapy for patients who require long-term treatment. For merchants interested in wholesaling fulvestrant, it is essential to highlight its proven efficacy, low toxicity profile, and long half-life in the bloodstream. It is also essential to provide dosage information, side effects, and proper administration guidelines to ensure that patients receive the maximum benefits of the drug.

Name: Fulvestrant

Fulvestrant is a prescription medicine used to treat advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic).

Indications

Monotherapy

Fulvestrant is indicated for the treatment of:

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or

HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.

Marketing Network

Focus on the enterprise purpose of "Take gene engineering as orientation, Render service to human health", the company adheres to serving the Chinese market as the main body and supporting some foreign markets as the auxiliary. Jiuyuan Marketing cultivates a professional, dedicated and enterprising pharmaceutical service team, establishes a stable, credible and efficient pharmaceutical service network, and focuses on timely delivery of high-quality pharmaceutical products which are the crystallization of scientific research, quality control and production, to the patients in urgent need, and efficient operation for safe, effective and economic use.

We have been pursuing to improve professional pharmaceutical service skills, expand the radiation capacity of pharmaceutical service network, and it is our constant pursuit to make Jiuyuan Pharmaceutical products and medical device to serve human health.

Marketing network spreads over the country more than 30 provinces and cities.

The industrial map continues to extend, and the company's products export to Asia, South America, Europe, Africa and many other countries.

Company Profile

Hangzhou Jiuyuan Genetic Engineering Co., Ltd. is a national high-tech enterprise specializing in the research and development, production and sales of genetic engineering drugs, orthopedic device products and chemical drugs. The company was established in December 1993. As a member of Hangzhou East China Pharmaceutical Group Holding Co., Ltd., it is one of the earliest genetic engineering pharmaceutical companies established in Zhejiang Province and even in the whole country.

Company Honor

National New High-tech Enterprise

Key New High-tech Enterprise of National Torch Plan

National superior enterprise of intellectual property

Provincial New High-tech Research & Development Center

Zhejiang Provincial Enterprise Technology Center

Zhejiang Famous Trademark

Zhejiang Jiuyuan Gene Engineering Biopharmaceutical Research Institute

Why choose us?

• Our Chinese factory is well-equipped to cater to small and large orders of Oncology Injection products with fast turnaround times.
• As our service tenet said we do what we said ,serve attentively. Our Persistent endeavors aim to win recognition from more customers.
• Our Chinese factory offers flexible pricing and customization options, making it easier for our customers to obtain the best shot at an affordable rate.
• The company sincerely hopes to cooperate sincerely with people of insight at home and abroad, create brilliant, and develop better products.
• At our factory, we understand the importance of timeliness, and we strive to deliver quality Oncology Injection products on time, every time.
• It is our future development road to insist on developing main industries and broadening fields.
• Our Chinese factory has an efficient supply chain system that ensures that our Oncology Injection products are readily available and accessible to our clients.
• We will make our due contribution to the Fulvestrant– An Anti-cancer Drug ,CAS No.: 129453-61-8 industry by adhering to the core values of continuous innovation, pursuit of perfection, attention to detail, responsibility and sincere cooperation.
• If you're looking for cost-effective Oncology Injection products without sacrificing quality, our Chinese factory is the right choice.
• Our company is a professional manufacturer of Fulvestrant– An Anti-cancer Drug ,CAS No.: 129453-61-8. The company has advanced processing equipment, various precision monitoring instruments and a full set of physical and chemical facilities, a good business environment and a team of high-quality professionals, advanced quality control methods, and the ability to respond quickly to market demand, so as to meet customer requirements for products.

Hot Tags: fulvestrant– an anti-cancer drug ,cas no.: 129453-61-8, China fulvestrant– an anti-cancer drug ,cas no.: 129453-61-8 manufacturers, suppliers, factory, cancer specification injection, tumor collaborator injection, tumor delivery injection, anti cancer supply injection, oncology retail injection, tumor injection